Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115492 · ClinicalTrials.gov registry record · Phase 4
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 797
- Enrollment target
- 20
- Study locations
NCT00115492 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 797 participants, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00115492, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 797 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.
Conditions Studied
Interventions
- DRUG Salmeterol
- DRUG Fluticasone Propionate/Salmeterol Combination Product
Study Locations (20)
Florida
- GSK Investigational Site - Atlantis
- GSK Investigational Site - Clearwater
- GSK Investigational Site - DeLand
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Pensacola
- GSK Investigational Site - Sarasota
- GSK Investigational Site - Tamarac
California
- GSK Investigational Site - Berkeley
- GSK Investigational Site - Fullerton
- GSK Investigational Site - Riverside
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Diego
- GSK Investigational Site - Vista
Alabama
- GSK Investigational Site - Jasper
- GSK Investigational Site - Mobile
Arizona
- GSK Investigational Site - Glendale
- GSK Investigational Site - Phoenix
Colorado
- GSK Investigational Site - Fort Collins
Connecticut
- GSK Investigational Site - Stamford
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 797 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115492
The ClinicalTrials.gov registry entry for NCT00115492 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 797 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,033-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (23% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Salmeterol is the first listed.
NCT00115492 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00115492 about?
NCT00115492 is a clinical study titled "Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations". This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All ...
What is the current status of trial NCT00115492?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 797 participants. The study started on 2004-12. Estimated completion is 2007-06.
What conditions does trial NCT00115492 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00115492?
The interventions under investigation include: Salmeterol (DRUG), Fluticasone Propionate/Salmeterol Combination Product (DRUG).
Who is sponsoring clinical trial NCT00115492?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115492 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
COMPLETED · Phase 4
-
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
COMPLETED · Phase 4
-
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
COMPLETED · Phase 4
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
COMPLETED · Phase 4
-
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
COMPLETED · Phase 4
-
Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.